1
项与 64Cu-DOTA-TLX592 相关的临床试验A Phase I, Single Centre, Open-label Study of TLX592 to Assess the Safety and Tolerability, Pharmacokinetics, Biodistribution and Radiation Dosimetry in Patients Diagnosed With Prostate Cancer
This is a Phase 1 trial of TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592). TLX592 is being developed as a PSMA-targeting antibody to be radiolabelled with a therapeutic radiosotope for the treatment of PSMA-expressing tumours, therefore this study has been designed to assess the safety and tolerability, pharmacokinetics, whole body biodistribution and radiation dosimetry of 64Cu-TLX592.
100 项与 64Cu-DOTA-TLX592 相关的临床结果
100 项与 64Cu-DOTA-TLX592 相关的转化医学
100 项与 64Cu-DOTA-TLX592 相关的专利(医药)
100 项与 64Cu-DOTA-TLX592 相关的药物交易